Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
Breaking up is hard to do when it comes to large pull requests, so GitHub is stacking things in favor of development teams ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results